CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled
Drug / intervention
Zilucoplandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06511076
NCT06511076Phase 1Completed

An Open-Label, Single Center, Randomized, 2-Way Crossover, Single-Dose, Bioequivalence Study of Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-Injector in Healthy Adult Participants

UCB Biopharma SRL·interventional·Posted Jul 19, 2024·Updated Jan 6, 2026

In Brief

A Phase 1 clinical trial evaluating Zilucoplan for Healthy Volunteers. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the bioequivalence pharmacokinetics, safety, tolerability and device deficiencies of zilucoplan (ZLP) in healthy adult participants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNetherlands
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedJul 19, 2024
Enrollment StartAug 5, 2024
Primary CompletionNov 26, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.0 years ago

Interventions

Zilucoplandrug

Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.